Provided By GlobeNewswire
Last update: Jul 9, 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company’s personalized off the shelf immunotherapy.
0.803
0 (-0.27%)
NASDAQ:BCTXZ (7/29/2025, 8:00:00 PM)
0.3399
+0.03 (+9.68%)
0.0484
0 (-2.81%)
Find more stocks in the Stock Screener